miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
Resistance to chemotherapy occurs in many ovarian cancer cases. Here, the authors show that mir-424(322) expression restores the sensitivity of ovarian cancer cells to chemotherapy by blocking the PD-L1 immune checkpoint, and find that combining immunotherapy and chemotherapy has a synergistic effec...
Guardado en:
Autores principales: | Shaohua Xu, Zhen Tao, Bo Hai, Huagen Liang, Ying Shi, Tao Wang, Wen Song, Yong Chen, Jun OuYang, Jinhong Chen, Fanfei Kong, Yishan Dong, Shi-Wen Jiang, Weiyong Li, Ping Wang, Zhiyong Yuan, Xiaoping Wan, Chenguang Wang, Wencheng Li, Xiaoping Zhang, Ke Chen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/83393a4ad9904862b71afa90aa143e94 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Neoadjuvant immune checkpoint inhibitor plus chemotherapy in rare tracheal tumors
por: Ben‐Yuan Jiang, et al.
Publicado: (2021) -
Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
por: Kennedy Yao Yi Ng, et al.
Publicado: (2021) -
The roles of exosomal immune checkpoint proteins in tumors
por: Cheng Xing, et al.
Publicado: (2021) -
Acta Nº322
por: Banco Central de Chile
Publicado: (2019) -
Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Zheng-Hang Wang, et al.
Publicado: (2018)